Menu Search
Equities

Advanced Medical Solutions Group PLC

AQA:FRA

Advanced Medical Solutions Group PLC

Actions
  • Price (EUR)2.38
  • Today's Change0.00 / 0.00%
  • Shares traded1.61k
  • 1 Year change0.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Advanced Medical Solutions Group plc is a United Kingdom-based independent developer and manufacturer of tissue-healing technology, focused on quality outcomes for patients. Its surgical products, including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand, RESORBA, LiquiBandFix8, LIQUIFIX, Peters Surgical, Ifabond, Vitalitec and Seal-G. It also supplies wound care dressings, such as silver alginates, alginates and foams through its ActivHeal brand, and under white label. Its Surgical Business Unit includes tissue adhesives, sutures, biosurgical devices and internal fixation devices. The Woundcare Business Unit comprises a multi-product portfolio of advanced wound care dressings and a portfolio of specialist medical bulk materials and multi-layer wound care products. Its products are manufactured in the United Kingdom, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel.

  • Revenue in GBP (TTM)131.11m
  • Net income in GBP11.13m
  • Incorporated1993
  • Employees1.50k
  • Location
    Advanced Medical Solutions Group PLCPremier Park, 33 Road OneWINSFORD CW7 3RTUnited KingdomGBR
  • Phone+44 160 686 3500
  • Fax+44 160 686 3600
  • Websitehttps://www.admedsol.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.